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Summary
The EphA2 receptor tyrosine kinase is frequently overexpressed in many cancers, including 40% of breast cancers. Here,
we show that EphA2 is a direct transcriptional target of the Ras-Raf-MAPK pathway and that ligand-stimulated EphA2
attenuates the growth factor-induced activation of Ras. Thus, a negative feedback loop is created that regulates Ras
activity. Interestingly, the expression of EphA2 and ephrin-A1 is mutually exclusive in a panel of 28 breast cancer cell lines.
We show that the MAPK pathway inhibits ephrin-A1 expression, and the ligand expression inhibits EphA2 levels contribut-
ing to the receptor-ligand reciprocal expression pattern in these cell lines. Our results suggest that an escape from the
negative effects of this interaction may be important in the development of cancer.S I G N I F I C A N C E
Ras is frequently hyperactivated in human tumors. Our results reveal that Ras activity is controlled by a negative feedback loop
through EphA2 in a ligand-dependent manner. Thus, deregulation of Eph signaling through downregulation of either receptor or
ligand expression may contribute to hyperactive Ras and tumor development.Introduction
Eph proteins form the largest family of receptor tyrosine ki-
nases in the human genome, with 16 Eph receptors and nine
ephrin ligands (Palmer and Klein, 2003).
Eph receptors and their ligands regulate axon guidance
(Brittis et al., 2002), cell migration (Knoll and Drescher, 2002;
McLennan and Krull, 2002; Sharfe et al., 2002; Wilkinson,
2000), morphogenesis (Miao et al., 2003), and vasculature (Bo-
venkamp and Greer, 2001; Ogawa et al., 2000).
There are two classes of ligands for Eph receptors: ephrin-A
and ephrin-B. A-type ephrins are anchored to the plasma
membrane via GPI linkage, whereas B-type ephrins have a
transmembrane domain and an intracellular domain. Depend-
ing on which type of ephrin they interact with, Eph receptors
are also classified as EphA or EphB. Upon ligand binding, Eph
receptors dimerize and become phosphorylated (Dodelet and
Pasquale, 2000).
Eph family members have been implicated in cellular trans-
formation, metastasis, and angiogenesis (Nakamoto and Ber-
gemann, 2002). EphA2 is overexpressed in a variety of can-
cers, including breast cancer (Zelinski et al., 2001), melanoma
(Easty et al., 1995), and prostate cancer (Walker-Daniels et
al., 1999).CANCER CELL : AUGUST 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INEphA2 has also been shown to play a role in malignant trans-
formation of MCF10A cells (Zelinski et al., 2001). In order to
determine the role of EphA2 in the initiation and/or progression
of cancer, it is important to understand how EphA2 levels are
regulated.
Activation of the EphA2 receptor has been shown to stimu-
late the mitogen-activated protein kinase (MAPK) pathway
(Pratt and Kinch, 2002) and the PI3K pathway (Pandey et al.,
1994). In contrast, others have shown that activated EphA2
downregulates the Ras/MAPK pathway (Miao et al., 2001) via
recruitment of p120GAP (Tong et al., 2003). A recent report
suggests that ligand binding upregulates EphA2 mRNA
through the MAPK pathway (Pratt and Kinch, 2003). Here, we
demonstrate that EphA2 is a direct transcriptional target of the
Ras-Raf-MAPK pathway and that ligand-stimulated EphA2 at-
tenuates the growth factor-induced activation of this pathway.
We propose that EphA2 signaling contributes to a feedback
loop that regulates Ras activity in a ligand-dependent manner.
We also show that EphA2 is expressed in a subset of breast
cancer cell lines and that the expression of EphA2 and its cog-
nate ligand, ephrin-A1, is inversely proportional in these cell
lines. Two distinct mechanisms contribute to the inverse corre-
lation between EphA2 receptor and ephrin-A1 ligand ex-
pression.C. DOI 10.1016/j.ccr.2005.07.005 111
A R T I C L EResults
Raf activation stimulates EphA2 mRNA
We analyzed transcriptional targets of the Raf-MEK-MAPK
pathway using microarrays consisting of 15,552 mouse cDNA
clones (Reynolds, 2002; VanBuren et al., 2002). RNA was gen-
erated from NIH3T3:RafAR cells that express a fusion protein,
comprised of an oncogenic form of human Raf-1 and the hor-
mone binding domain of an androgen receptor. Upon androgen
addition, Raf kinase activity and the MAP kinase pathway are
activated (Samuels et al., 1993; Shelton et al., 2003).
Serum-starved NIH3T3:RafAR cells were stimulated with
300 nM testosterone or ethanol for 24 hr. RNA was isolated,
differentially labeled with cy3/cy5, and hybridized to the cDNA
microarrays (DeRisi et al., 1996). The arrays were scanned and
analyzed using GenePix 3.0 software. Results were compiled
from three separate experiments, each performed in duplicate.
In response to MAPK activation, EphA2 expression was stim-
ulated 3.5- to 5-fold. Cyclin D1, a previously described down-
stream target of Raf, was stimulated 3-fold in the same experi-
ment (data not shown). To validate the microarray results, we
performed a Northern blot with RNA prepared from NIH3T3:
RafAR cells as described above and using EphA2 cDNA as
probe. A single transcript was found to be stimulated upon
treatment with testosterone (Figure 1A).Figure 1. EphA2 is a transcriptional target of the Raf/MAPK pathway
A: Raf activation stimulates EphA2 mRNA. NIH3T3:RafAR cells were serum
starved for 32 hr prior to treatment with either 300 nM testosterone or etha-
nol for 24 hr. The Northern blot was probed with 32P-labeled EphA2 cDNA.
Total RNA served as the loading control.
B: Raf activation stimulates the EphA2 protein. Serum-starved NIH3T3:
RafAR cells were treated with either 300 nM testosterone for 1, 4, or 24 hr,
or ethanol (labeled as 0). The Western blot was probed with an anti-EphA2
monoclonal antibody. Phospho-Erk and p21/Cip1 served as positive con-
trols for Raf activation. Total Erk served as the loading control.
C: Inhibition of the MAPK pathway inhibits EphA2 levels. Breast cell lines
were treated with either 10 MMEK inhibitor U0126 (Promega) or DMSO for
24 hr. Cell lysates were analyzed for EphA2 protein expression. P-Erk served
as a positive control for MEK activity, and T-Erk served as the loading
control.112To test if the MAPK pathway directly activates transcription
of EphA2, we treated NIH3T3 cells harboring Raf fusion con-
struct described above with 20 g/ml cycloheximide 15 min
prior to stimulating Raf and measured EphA2 mRNA expres-
sion by quantitative RT-PCR. Cycloheximide did not prevent
EphA2 mRNA induction, showing that transcriptional activation
of EphA2 by MAPK did not depend on new protein synthesis
(data not shown).
Raf activation stimulates EphA2 protein levels
To determine if Raf activation also increases levels of EphA2
protein, serum-starved NIH3T3:RafAR cells were stimulated
as described above but for 1, 4, or 24 hr. Cell extracts were
prepared and resolved on an SDS-PAGE gel, and protein levels
were analyzed by Western blotting with a monoclonal anti-
EphA2 antibody. EphA2 protein levels increased within 1 hr of
Raf activation, with further increases at 4 and 24 hr time points
(Figure 1B). As described previously, acute activation of Raf
kinase also induced expression of p21/Cip1 (Figure 1B) and
cyclin D1 (data not shown).
To rule out the possibility that activation of EphA2 by the
MAPK pathway in NIH3T3:RafAR cells may be an effect of tes-
tosterone or unique to fibroblasts, we examined the effect of
MAPK activation on EphA2 levels in immortalized but non-
transformed human breast epithelial MCF10A:RafER cells
(Schulze et al., 2001). These cells express a RafER fusion pro-
tein that can be activated by addition of 4-hydroxy tamoxifen
(Samuels et al., 1993). As expected, the hormone treatment
induced Raf activity and EphA2 protein levels (Figure 5A).
These results support our microarray and Northern data and
indicate that EphA2 is a downstream target of the Raf/MAPK
pathway.
EphA2 protein levels are inhibited by inhibition
of MEK activity
To further confirm EphA2 as a target of the MAPK pathway, we
examined EphA2 protein levels in MDA-MB231, MDA-MB435,
BT549, and MCF10A breast cell lines in the presence or ab-
sence of MEK inhibitor U0126 (Promega). Cells were treated
with either 10 M U0126 or DMSO for 24 hr. EphA2 protein
levels were analyzed by Western blotting with an anti-EphA2
antibody. As shown in Figures 1C and 5B, EphA2 protein levels
were inhibited by U0126. Another well-characterized MEK in-
hibitor, PD 98059, had similar effect on EphA2 levels (Figure
5B). This confirms our results that EphA2 is a target of the Raf/
MAPK pathway.
Ligand-stimulated EphA2 attenuates EGF-induced
activation of the MAPK pathway
Eph-ephrin interaction results in the Eph receptor being phos-
phorylated (Dodelet and Pasquale, 2000). We noticed that this
treatment downregulated P-Erk levels in HBL100 cells (data
not shown). To characterize this further, we exposed serum-
starved BT549, MDA-MB157, HBL100, MDA-MB231, and
MCF10A cells to a soluble ephrin ligand, ephrin-A1/Fc, and
measured its effects on ERK phosphorylation following EGF
treatment. Figure 2 shows that, in most cases, the stimulation
of ERK phosphorylation in response to EGF was reduced sig-
nificantly following the activation of EphA2 by ephrin-A1 ligand
(MCF10A data not shown). The exception was MDA-MB231:
in these cells, the levels of P-Erk were independent of EGF andCANCER CELL : AUGUST 2005
A R T I C L EFigure 2. Ligand-mediated EphA2 stimulation attenuates the EGF-induced
activation of the MAPK pathway
Cells were serum starved for 24 hr, pretreated with 1 g/ml ephrin-A1/Fc
for 5 min, and then stimulated with 10 ng/ml EGF for 2, 5, or 10 min (BT549
cells were stimulated with 1 ng/ml EGF). MAPK activity was assessed using
a polyclonal anti-phospho-Erk antibody.ephrin ligand, probably because this cell line harbors a muta-
tion in B-Raf (Wilhelm et al., 2004) and an activated allele of
K-Ras (Kozma et al., 1987; Ogata et al., 2001) that does not
require EGF for activation and cannot be downregulated by the
recruitment of p120GAP. Indeed, stable expression of H-RasV12
in BT549 cells that express normal levels of Ras renders them
insensitive to inhibition of EGF-induced activation of P-Erk by
ligand-stimulated EphA2 (data not shown).
EphA2 and ephrin-A1 expression is inversely proportional
in breast cancer cell lines
We have shown that the MAPK pathway activates EphA2 ex-
pression and that ligand-stimulated EphA2 downregulates
P-Erk levels. This prompted us to propose that EphA2 signaling
may regulate Ras activity through a negative autocrine loop
where ephrin ligand activates EphA2 cell autonomously. To ex-
plore this possibility, we examined the expression of EphA2
and its ligands in a panel of breast cancer cell lines in which
gene expression profiles, gene copy number, and a number of
biochemical properties have been examined comprehensively
(K. Chin, R.M.N., F.M., and J.W.G., unpublished data). We
found an inverse correlation between the expression of EphA2
receptor and ephrin-A1 ligand (Figure 3A). EphA2 protein was
expressed in 8 of 28 cell lines tested. These eight cell lines
express molecular markers of a mesenchyme-like phenotype:
they fail to express E-cadherin, for example, and express high
levels of vimentin (L. Timmerman, J.Y., J.W.G., and F.M., un-
published data). Each of these cell lines is ER negative (J.
Gump and F.M., unpublished data), confirming their lack of
breast epithelial characteristics (Sorlie et al., 2001). Cells ex-
pressing the highest level of EphA2 mRNA (MDA-MB231) also
express a mutant, activated Ras and mutant B-Raf, confirming
the relationship between MAPK activation and EphA2 ex-
pression.
In contrast, cells expressing the highest levels of ephrin-A1
ligand were those with epithelial characteristics (E-cadherin ex-
pression, no vimentin), such as the well-characterized SK-BR3
cells (L. Timmerman, J.Y., J.W.G., and F.M., unpublished data).
EphA2 and ephrin-A1 protein levels corresponded well with
mRNA levels (Figure 3B). Ephrin-A2 and -A5 were not ex-
pressed in these cells, while the pattern of ephrin-A3 and
-A4 mRNA levels paralleled that of ephrin-A1 (Figure 3B). Thus,
amongst this panel of breast cancer cell lines, none appear to
express both ligand and receptor and therefore none maintains
negative feedback of Ras signaling through EphA2 activation.CANCER CELL : AUGUST 2005Ephrin-A1 suppresses EphA2 protein levels
Breast cancer cells that express ephrin-A ligands fail to ex-
press EphA2. Therefore, we addressed the possibility that, in
these cells, ephrin ligand inhibits the expression of EphA2. In-
deed, ephrin-A1 siRNA enhanced EphA2 protein levels signifi-
cantly in SK-BR3 (Figure 4A) and BT474 cells (data not shown).
On the other hand, ectopic expression of ephrin-A1 downregu-
lated EphA2 protein levels in MDA-MB231 and BT549 cells
(Figure 4B). Taken together, these results strongly indicate that
the expression of ephrin-A1 suppresses EphA2 protein levels.
Increased expression of EphA2 following knockdown of ligand
expression is not due to activation of the MAPK pathway
(levels of phospho-ERK do not change following ephrin knock-
down; data not shown) and must involve yet another element
of crosstalk and regulation.
One possible mechanism for downregulation of the EphA2
receptor by the ephrin ligand described above may involve li-
gand-mediated receptor internalization. To explore this possi-
bility, we treated EphA2-expressing HBL100 cells with soluble
ephrin-A1/Fc for 1, 3, or 7 hr and examined EphA2 localization
by immunofluorescence. EphA2 staining was redistributed
from plasma membrane within 1 hr after treatment with ephrin-
A1/Fc, and decreased EphA2 staining was observed after
longer exposures (Figure 4C). Similar results were obtained
with MDA-MB231 and BT549 cells (data not shown). Treatment
with Fc alone had no effect on EphA2 staining pattern (data not
shown). We conclude that cells expressing the ephrin ligand
suppress EphA2 expression, at least in part, through ligand-
dependent receptor internalization (Figure 4C) and degradation
(Walker-Daniels et al., 2002).
The MAPK pathway suppresses expression of ephrin-A1
We have shown that breast cancer cells that express EphA2
do not express ephrin-A1 ligand and that EphA2 expression in
these cells is regulated, at least in part, by the MAPK pathway.
We considered the possibility that ephrin-A1 ligand in these
cells is suppressed by this pathway based on the recent dis-
covery that active β-catenin both activates transcription of
EphB receptor and downregulates ephrin-B ligand, to deter-
mine cell fate in the intestinal epithelium (Batlle et al., 2002).
Indeed, the activation of the MAPK pathway in MCF10A:
RafER cells by 4-hydroxy tamoxifen inhibited levels of ephrin-
A1 (Figure 5A), and the inhibition of MAPK activity by MEK in-
hibitors UO126 and PD 98059 increased ephrin-A1 levels (Fig-
ure 5B). We conclude that the lack of ephrin-A1 expression in
our panel of breast cancer cell lines expressing the EphA2 re-
ceptor may be due, in part, to inhibition of ephrin-A1 expres-
sion by MAPK signaling.
Ephrin-A1 presented on neighboring cells
can activate the EphA2 receptor
We have shown that the MAPK pathway both activates tran-
scription of the EphA2 receptor and inhibits ephrin-A1 levels.
Therefore, we reasoned that the ligand-induced activation of
EphA2 is non-cell-autonomous and via ligand presented on
neighboring cells such as the stromal cells. To address this
possibility, we cocultured BT549 (receptor-expressing) and
T47D (ligand-expressing) cells and examined tyrosine phos-
phorylation on EphA2 after immunoprecipitating the EphA2 re-
ceptor with an anti-EphA2 antibody. Treatment with soluble
ephrin-A1/Fc served as a positive control. Indeed, EphA2 was113
A R T I C L EFigure 3. Expression of EphA2 and its ligand,
ephrin-A1, is inversely proportional in breast
cancer cell lines
A: Extracts were prepared from 28 different
breast cell lines (note: HBL100 cell line is re-
ported to have a Y chromosome). Ten micro-
grams of total protein was resolved on SDS-
PAGE gels, transferred to PVDF membranes, and
probed with either an anti-EphA2 or an anti-
ephrin-A1 antibody. A monoclonal anti-actin
antibody was used to ensure equal loading.
B: Affymetrix array analysis of EphA2 and ephrin-A
mRNA expression in 39 breast cancer cell lines.
Expression levels are represented by bar graphs.
x axis, cell lines; y axis, relative expression;
EphA2, blue color; ephrin-A, red color. Order of
cell lines from left to right: 1, HCC1428; 2, BT483;
3, MDA-MB134; 4, T47D; 5, ZR75-1; 6, SUM-44PE; 7,
MDA-MB361; 8, BT474; 9, MDA-MB453; 10, SUM-
52PE; 11, MDA-MB435; 12, ZR75-30; 13, MDA-
MB415; 14, HCC1569; 15, MCF7A; 16, LY2; 17,
HCC1143; 18, HCC3153; 19, SK-BR3; 20,
HCC1007; 21, HCC2185; 22, HCC1937; 23,
HCC2157; 24, 600MPE; 25, MDA-MB436; 26,
MDA-MB468; 27, HCC202; 28, BT549; 29, MDA-
MB157; 30, HBL100; 31, BT20; 32, SUM-149PT; 33,
ZR75B; 34, DU4475; 35, HS578T; 36, HCC38; 37,
HCC1954; 38, MDA-MB231; 39, SUM-159PT.tyrosine phosphorylated when presented with the ligand-
expressing T47D cells (Figure 6), indicating that the inhibition
of Ras activity by ligand-stimulated EphA2 is not an autocrine
event, but rather occurs through binding to ligand presented
on neighboring cells.
Ephrin expression inhibits transformation
by v-ErbB in NIH3T3 cells
The ligand-stimulated EphA2 attenuates the EGF-induced acti-
vation of the Ras/MAPK pathway. This suggests that EphA2
signaling plays an important role in regulating Ras activity. We
inquired if the ligand-induced activation of EphA2 inhibits
transformation by v-ErbB, an event known to be dependent on
Ras activation (McCubrey et al., 2004). The expression of
ephrin-A1 suppressed v-ErbB transformation significantly, as114determined by the reduction in colony formation in soft agar
(Figure 7). In contrast, NIH3T3 cells transformed with H-RasV12
formed colonies at the same efficiency in the absence or pres-
ence of ephrin expression (data not shown). NIH3T3 cells ex-
pressing an empty vector had no colonies (data not shown).
Taken together, these data are consistent with the role of
EphA2 signaling in regulation of Ras activity, support our nega-
tive feedback loop model (Figure 8), and suggest a biological
role of EphA2 signaling in tumorigenesis.
Discussion
A negative feedback loop regulates Ras activity
through EphA2 in a ligand-dependent manner
Normal cells respond to growth factor stimulation by turning
on the MAPK pathway, resulting in cell proliferation, cell differ-CANCER CELL : AUGUST 2005
A R T I C L EFigure 4. Ephrin-A1 suppresses EphA2 protein levels
A: SK-BR3 cells were transiently transfected with ephrin-A1 siRNA smartpool
from Dharmacon. Cells were harvested 48 hr after transfection. Lysates
were analyzed for EphA2 and ephrin-A1 protein expression. Total Erk served
as the loading control.
B: MDA-MB231 and BT549 cells were stably transfected with either an
empty vector or ephrin-A1 cDNA. Lysates were analyzed for EphA2 and
ephrin-A1 protein expression. Total Erk served as the loading control.
C: HBL100 cells were grown in 8-well dishes and treated with 1 g/ml solu-
ble ephrin-A1/Fc for 1, 3, or 7 hr. Cells were fixed and labeled with a mono-
clonal anti-EphA2 antibody for 1 hr followed by Alexa 488 secondary anti-
body. Nuclei were counterstained with DAPI. Cells were visualized by
confocal microscopy.Raf activation stimulates EphA2 mRNA expression and protein
Figure 5. MAPK pathway activates transcription of EphA2 and downregu-
lates ephrin-A1 levels in breast epithelial cells
A: MCF10A:RafER cells were serum starved for 32 hr prior to treatment
with either 300 nM 4-hydroxy tamoxifen for 4 or 24 hr, or ethanol (labeled as
0). The Western blot was probed with an anti-EphA2 monoclonal antibody.
Phospho-Erk served as the positive control for Raf activation, and total Erk
served as the loading control.
B: MCF10A cells were treated with 10 M MEK inhibitors U0126 (U) or PD
98059 (PD) for 24 hr. The Western blot was probed with anti-EphA2 and
anti-ephrin-A1 antibodies. P-Erk served as a positive control for MEK activ-
ity, and total Erk served as the loading control.CANCER CELL : AUGUST 2005Figure 6. EphA2 receptor is phosphorylated by ephrin-A1 ligand presented
on neighboring cells in coculture
Receptor-expressing BT549 cells were either incubated with soluble ephrin-
A1/Fc (EA1/Fc) ligand or cocultured with ephrin-expressing T47D cells for 1
hr. Cells were lysed. The EphA2 protein was immunoprecipitated with an
anti-EphA2 antibody and analyzed for phosphotyrosine content by West-
ern blotting using a monoclonal anti-phosphotyrosine antibody (pY).acterized of this latter type: they display a fibroblast-like mor-
Figure 7. Ephrin-A1 inhibits transformation of NIH3T3 cells by v-ErbB in soft
agar
Colony formation by v-ErbB was compared in the absence or presence of
ephrin-A1 expression in NIH3T3 cells. Colonies were counted and graphed.
The error bars represent an average of triplicates. The experiment was re-
peated twice.entiation, and other cellular processes. Hyperactivation or de-
regulation of this pathway is responsible for many human can-
cers. Mechanisms exist to maintain homeostasis in normal
cells. Our results point to one such mechanism. We show thatlevels. This may account for high levels of EphA2 in many can-
cer cells, such as in malignant melanoma, in which the Ras-
Raf-MAPK pathway is invariably activated, through activation
of either Ras or B-Raf (Davies et al., 2002). We, and others,
also show that EphA2 attenuates growth factor-induced activa-
tion of the MAPK pathway in a ligand-dependent manner, pos-
sibly through p120GAP. Taken together, these results indicate
that the interplay between growth factor-induced Ras signaling
and EphA2 receptor kinase signaling forms a conditional feed-
back loop that regulates Ras activity (Figure 8).
We explored the possibility that a negative autocrine loop
regulates Ras activity, in which ephrin ligand activates EphA2
receptor cell autonomously. Our results indicate that this is not
likely. Examination of a large panel of breast cancer cell lines
revealed that expression of EphA2 and its ligands is mutually
exclusive. One explanation for this striking relationship appears
to be that cells expressing ephrin ligand are of a different origin
or lineage than those expressing EphA2. The expression of
A-type ephrins (A1, A3, and A4) is restricted to cells that retain
epithelial cell markers, and EphA2 is expressed in cells with
mesenchyme characteristics (L. Timmerman, J.Y., J.W.G., and
F.M., unpublished data). MDA-MB231 cells are the best char-115
A R T I C L EFigure 8. Model: A conditional feedback loop regulates Ras activity
through EphA2
The MAPK pathway controls the expression of the EphA2 receptor and its
ligand, ephrin-A1. Upon binding to ephrin-A1 (shown as a gray knob), the
EphA2 receptor (shown in black) is phosphorylated, and the EGF-induced
activation of the MAPK pathway is attenuated.phology and grow as invasive colonies in matrigel, for example.
They are an unusual example of a breast carcinoma cell that
harbors mutant, activated K-Ras and B-Raf alleles. These cells
have high constitutive levels of MAPK activity, and the highest
level of EphA2 amongst the cells we examined. In these cells,
elevated MAPK contributes to the suppression of ephrin ex-
pression: inhibition of the MAPK pathway induces ephrin ex-
pression while reducing EphA2 expression. The ability of the
MAPK pathway to upregulate EphA2 while downregulating its
ligand has a striking parallel: recently it was reported that
β-catenin both activates transcription of EphB receptor and
downregulates ephrin-B ligand, to determine cell fate in the
intestinal epithelium (Batlle et al., 2002). It is possible that
MAPK-EphA2 signaling plays a similar role in the organization
of breast acini, but this remains to be proven. In breast cancer
cells of the epithelial type, the expression of ephrin ligand con-
tributes to EphA2 suppression, through a mechanism that
consists, at least in part, of ligand-mediated receptor internal-
ization (Figure 4E) and degradation (Sharfe et al., 2003; Walker-
Daniels et al., 2002) but must also involve other regulatory pro-
cesses that suppress EphA2 expression at the mRNA level.
Interestingly, these cells have high levels of MAPK activity, but
ephrin levels appear to be refractory to inhibition by MAPK.
How these cells escape inhibition of ephrin by MAPK remains
to be determined.
Finally, our results suggest that tumor cells whose pheno-
type depends on hyperactive Ras signaling may be sup-
pressed by neighboring cells that present ephrin ligand on their
cell surface, and that an escape from the negative effects of
this interaction may be a necessary step in the development
of such cancers.
Experimental procedures
Cell lines and cell culture
The NIH3T3:RafAR and MCF10A:RafER cell lines were received as gifts
from Dr. Martin McMahon. The NIH3T3:v-ErbB cell line was a gift from Dr.116Bill Weiss’s laboratory. The breast cancer cell lines are part of the Breast
Cancer SPORE project. Cells were grown at 5% CO2 in DMEM or RPMI (as
recommended by ATCC) containing 10% fetal bovine serum. Cells were
serum starved for 24–32 hr prior to stimulation with hormone or EGF. Solu-
ble ephrin-A1/Fc chimera and Fc were purchased from R&D Systems. EGF
was purchased from Invitrogen. For coculture, ephrin-expressing T47D cells
were harvested from a confluent plate, mixed with a subconfluent culture
of EphA2 receptor-expressing BT549 cells, and incubated for 1 hr in a
CO2 incubator.
RNA preparation
Serum-starved NIH3T3:RafAR cells were treated with 300 nM testosterone
(Sigma) to stimulate the MAPK pathway. Total RNA was prepared using
Qiagen’s midi prep kit, and mRNA was prepared using Invitrogen’s Fast-
Track kit.
cDNA clones and microarray analysis
A set of 15,552 mouse cDNA clones, consisting of 8,832 Incyte clones and
6,720 NIA clones obtained from the UCSF mouse consortium facility, were
printed on glass slides (DeRisi et al., 1996). Typically, 1 g mRNA or 10 g
total RNA were differentially labeled with Cy3 or Cy5 and used to hybridize
the arrays for 16 hr and then washed (DeRisi et al., 1996). The arrays were
scanned and analyzed using GenePix 3.0 software. The EphA2 and ephrin-
A1 cDNA clones were obtained as gifts from Dr. Nigel Carter (Hunter Lab).
Northern blotting and quantitative RT-PCR
Ten micrograms of total RNA was resolved on a 1% formaldehyde gel. Nu-
cleic acids were transferred to Hybond-N membrane (GE Healthcare) and
probed with 32P-labeled EphA2 cDNA. The membrane was autoradio-
graphed using Hyper film from GE Healthcare. Quantitative RT-PCR was
performed at the UCSF Cancer Center Genome core facility using an EphA2
primer set from Applied Biosciences.
Transfection
Cells were transfected with Lipofectamine 2000 per Invitrogen’s transfection
protocol and harvested 48 hr after transfection. To make stable cell lines,
transfected cells were selected for drug resistance inherent to the plasmid
construct. For siRNA transfections, 5 g of siRNA smartpool from Dhar-
macon were transiently transfected into cells. To increase transfection effi-
ciency, cells were retransfected 24 hr later and harvested 48 hr after the
first transfection.
Protein gel electrophoresis and Western blotting
Cells were lysed in TNE buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM
EDTA) containing 1% NP40, 1 mM DTT, protease inhibitor cocktail, and
phosphatase inhibitor cocktails I and II from Sigma. Protein concentration
was measured using BioRad’s Lowry assay kit. Typically, 20 g of total
protein was resolved on 4%–20% Tris glycine SDS-PAGE gels (Invitrogen).
Proteins were transferred to PVDF membranes (Millipore). Antibodies were
used as recommended by the vendor. Primary antibodies used were as
follows: polyclonal phospho-Erk and total Erk antibodies (Cell Signaling),
monoclonal p21/Cip1 antibody (Becton Dickinson), monoclonal EphA2 and
phospho-tyrosine 4G10 antibodies (Upstate), and anti-goat ephrin-A1 anti-
body (R&D Systems). Horseradish peroxidase (HRP)-conjugated secondary
antibodies were as follows: anti-mouse (GE Healthcare), anti-rabbit (Cell
Signaling), and anti-goat (Santa Cruz). Western blots were developed using
enhanced chemiluminescence (ECL; GE Healthcare).
Immunofluorescence
EphA2-expressing cells were grown in 8-well chamber slides and treated
with either 1 g/ml soluble ephrin-A1/Fc or Fc for 0, 1, 3, or 7 hr. Cells were
fixed with 4% paraformaldehyde and incubated with a monoclonal anti-
EphA2 antibody for 1 hr followed by Alexa 488 secondary antibody (Molec-
ular Probes). Cells were visualized by confocal microscopy.
Soft agar assay
NIH3T3 cells stably expressing either an empty vector or v-ErbB in the
absence or presence of ephrin-A1 expression were mixed with 0.6% Sea
Plaque agarose and plated in 6-well dishes (105 cells per well) containing a
1% Sea Plaque agarose cushion. Cells were allowed to grow at 37°C. Me-CANCER CELL : AUGUST 2005
A R T I C L Edia were replenished once a week until colonies became visible. Colonies
were stained overnight with 0.015% Neutral Red (Sigma #N-2889) and
counted.
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